Increased risk of myelotoxicity in elderly patients with non-hodgkin lymphoma - The case for routine prophylaxis with colony-stimulating factor beginning in the first cycle of chemotherapy

被引：37

作者：

Balducci, L

Repetto, L

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Senior Adult Oncol Program, Tampa, FL 33612 USA

[2] Ist Nazl Riposa & Cura Anziani, Unita Operat Geriatria Oncol, Rome, Italy

来源：

CANCER | 2004年 / 100卷 / 01期

关键词：

myelotoxicity; neutropenia; elderly; chemotherapy; colony-stimulating factor (CSF); non-Hodgkin lymphoma (NHL);

D O I：

10.1002/cncr.11861

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neutropenia is the major dose-limiting toxicity of myelosuppressive chemotherapy in patients with cancer. Because of the high incidence of neutropenic complications and death in the early cycles of chemotherapy and the potential for improved outcomes, prophylaxis with colony-stimulating factor beginning in the first cycle should be routinely considered in elderly patients with non-Hodgkin lymphoma who are treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like chemotherapy regimens.

引用

页码：6 / 11

页数：6

共 38 条

[11] REDUCTION BY GRANULOCYTE COLONY-STIMULATING FACTOR OF FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER [J].

CRAWFORD, J ;

OZER, H ;

STOLLER, R ;

JOHNSON, D ;

LYMAN, G ;

TABBARA, I ;

KRIS, M ;

GROUS, J ;

PICOZZI, V ;

RAUSCH, G ;

SMITH, R ;

GRADISHAR, W ;

YAHANDA, A ;

VINCENT, M ;

STEWART, M ;

GLASPY, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :164-170

[12] EFFECT OF AGE ON THERAPEUTIC OUTCOME IN ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].

DIXON, DO ;

NEILAN, B ;

JONES, SE ;

LIPSCHITZ, DA ;

MILLER, TP ;

GROZEA, PN ;

WILSON, HE .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) :295-305

[13] Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on US cancer burden [J].

Edwards, BK ;

Howe, HL ;

Ries, LAG ;

Thun, MJ ;

Rosenberg, HM ;

Yancik, R ;

Wingo, PA ;

Jemal, A ;

Feigal, EG .

CANCER, 2002, 94 (10) :2766-2792

[14]

EPELBAUM R, 1990, CANCER-AM CANCER SOC, V66, P1124, DOI 10.1002/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO

[15]

2-T

[16] Risk factors for treatment-related death in elderly patients with aggressive non-Hodgkin's lymphoma:: Results of a multivariate analysis [J].

Gómez, H ;

Hidalgo, M ;

Casanova, L ;

Colomer, R ;

Pen, DLK ;

Otero, J ;

Rodríguez, W ;

Carracedo, C ;

Cortés-Funes, H ;

Vallejos, C .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2065-2069

[17] A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy [J].

Green, MD ;

Koelbl, H ;

Baselga, J ;

Galid, A ;

Guillem, V ;

Gascon, P ;

Siena, S ;

Lalisang, RI ;

Samonigg, H ;

Clemens, MR ;

Zani, V ;

Liang, BC ;

Renwick, J ;

Piccart, MJ .

ANNALS OF ONCOLOGY, 2003, 14 (01) :29-35

[18]

GREGORY SA, 2000, P AN M AM SOC CLIN, V19, pA15

[19] Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer [J].

Holmes, FA ;

O'Shaughnessy, JA ;

Vukelja, S ;

Jones, SE ;

Shogan, J ;

Savin, M ;

Glaspy, J ;

Moore, M ;

Meza, L ;

Wiznitzer, I ;

Neumann, TA ;

Hill, LR ;

Liang, BC .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :727-731

[20] PROGNOSTIC-SIGNIFICANCE OF ACTUAL DOSE INTENSITY IN DIFFUSE LARGE-CELL LYMPHOMA - RESULTS OF A TREE-STRUCTURED SURVIVAL ANALYSIS [J].

KWAK, LW ;

HALPERN, J ;

OLSHEN, RA ;

HORNING, SJ .

JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (06) :963-977

← 1 2 3 4 →